Kevin Norris, MD
Family Medicine · Salina, KSNPI 1063477966
Payments from drug & device makers
Across 112 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$363
- Amgen$186
- Novo Nordisk$142
- Lilly USA, LLC$138
- AbbVie$134
- Novartis$105
- plus $557 from 22 others
What the payments were for
- Food & beverage$1,626100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $363 |
| Amgen | 14 | $186 |
| Novo Nordisk | 8 | $142 |
| Lilly USA, LLC | 9 | $138 |
| AbbVie | 6 | $134 |
| Novartis | 7 | $105 |
| AstraZeneca | 6 | $81 |
| GSK | 5 | $79 |
| Merck | 4 | $58 |
| Astellas Pharma US Inc | 4 | $50 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Abbott | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,626 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $103,072 |
| EliquisApixaban | 178 | $89,587 |
| JanuviaSitagliptin Phosphate | 88 | $57,005 |
| FarxigaDapagliflozin Propanediol | 28 | $21,885 |
| MyrbetriqMirabegron | 40 | $16,064 |
| JardianceEmpagliflozin | 26 | $14,930 |
| TrulicityDulaglutide | 15 | $14,368 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,261 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,897 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 294 | $6,789 |
| TradjentaLinagliptin | 25 | $6,561 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,097 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,221 |
| Enoxaparin Sodium | 18 | $4,122 |
| Potassium Chloride | 198 | $4,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $142 | $103,072109 claims |
| PfizerEliquis, Dilantin | $363 | $91,423191 claims |
| MerckJanuvia | $58 | $57,00588 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $13 | $27,58764 claims |
| AstraZenecaFarxiga | $81 | $21,88528 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $16,06440 claims |
| Lilly USA, LLCTrulicity | $138 | $14,36815 claims |
| GSKAnoro Ellipta | $79 | $8,26118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Salina
- Son NguyenSalina$17K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.